Chandra Bhagat Pharma Limited has announced the establishment of a new international office in Dubai, United Arab Emirates, marking a significant step in the company's global expansion strategy. The pharmaceutical company informed BSE Limited about this development on April 1, 2026, in compliance with Regulation 30 of SEBI listing requirements.

Office Establishment Details

The new Dubai office represents a strategic move to strengthen the company's international presence and tap into global markets. The facility will serve as an International Business/Representative Office, positioning the company to better serve international clients and partners.

Strategic Objectives

The establishment of the Dubai office aligns with Chandra Bhagat Pharma Limited's strategic growth plans and serves multiple business objectives:

• Expand global footprint in international pharmaceutical markets
• Enhance export opportunities and international trade capabilities
• Strengthen relationships with international clients and business partners
• Facilitate better market access in the Middle East and North Africa region

Regulatory Compliance and Documentation

The company has obtained its Certificate of Formation from the Sharjah Media City Free Zone Authority (Shams), established pursuant to Amiri Decree No. 11 for the year 2017. The certificate confirms the formation of Chandra Bhagat Pharma Limited Branch with formation date of March 31, 2026.

Director Pranav H Bhagat (DIN No. 00156362) signed the regulatory filing, ensuring compliance with all applicable listing obligations and disclosure requirements. The company has satisfied all requirements under the rules and regulations of Sharjah Media City Free Zone Authority for the establishment of the branch office.

Business Impact

This international expansion initiative represents Chandra Bhagat Pharma Limited's commitment to enhancing its global business operations and market reach. The Dubai office is expected to serve as a key hub for the company's international activities, facilitating improved access to Middle Eastern and global pharmaceutical markets while supporting the company's long-term growth strategy.

Chandra Bhagat Pharma Limited has informed BSE that corporate governance provisions under SEBI regulations are not applicable to the company for the quarter ended December 31, 2025. The filing was made on January 21, 2026, under Regulation 15 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Exemption Details

The company cited its listing on the SME Exchange as the basis for exemption from corporate governance requirements. Under SEBI Regulation 15, entities listed on SME exchanges are exempt from compliance with specific corporate governance provisions.

Corporate Governance Provisions Not Applicable

The exemption covers multiple regulations under SEBI (LODR) Regulations, 2015. Chandra Bhagat Pharma Limited is not required to comply with Regulations 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, and 27. Additionally, the company is exempt from clauses (b) to (i) and (t) of sub-regulation (2) of Regulation 46, along with paragraphs C, D, and E of Schedule V.

SME Exchange Benefits

SEBI provides two categories of exemptions from corporate governance requirements:

• Listed entities with paid-up equity share capital not exceeding ₹10.00 crore and net worth not exceeding ₹25.00 crore as on the last day of the previous financial year
• Listed entities with specified securities listed on SME exchanges

Chandra Bhagat Pharma Limited falls under the second category due to its SME Exchange listing. This exemption eliminates the requirement to submit Corporate Governance Reports for the specified quarter.

Filing Authority

The certificate was signed by Rajni Dawani, Company Secretary and Compliance Officer of Chandra Bhagat Pharma Limited. The communication was addressed to the Manager – Listing Compliance, Department of Corporate Service at BSE Limited, Mumbai.